Background/Aim This study evaluated real-life adalimumab impact in patients with active non-infectious intermediate, posterior, or panuveitis (NIIPPU). Methods Adults with active NIIPPU received adalimumab in this prospective, observational study (06/2017–04/2020). Patients were evaluated at baseline (V0) and four follow-up visits over 12 months (V1–V4). Primary endpoint: proportion of patients achieving quiescence (anterior chamber (AC) cells grade and vitreous haze (VH) grade≤0.5+ in both eyes, no new active chorioretinal lesions) at any follow-up visit. Secondary endpoints: proportion of patients achieving quiescence at each visit; proportion of patients maintaining response; and proportion of patients with flares. Workability, visual function, healthcare resource utilisation, and safety were evaluated. Results Full analysis set included 149 patients. Quiescence at any follow-up visit was achieved by 129/141 (91%) patients. Quiescence at individual visits was achieved by 99/145 (68%), 110/142 (77%), 102/131 (78%), and 99/128 (77%) patients at V1–V4, respectively. Number of patients in corticosteroid-free quiescence increased from 51/147 (35%; V1) to 67/128 (52%; V4; p<0.05). Proportion of patients with maintained response increased from 89/141 (63%; V2) to 92/121 (76%; V4; p<0.05) and proportion of patients with flare decreased from 25/145 (17%; V1) to 13/128 (10%; V4; p=0.092). Workability and visual function improved throughout the study. Proportion of patients with medical visits for uveitis decreased from 132/149 (89%; V0) to 27/127 (21%; V4). No new safety signals were observed. Conclusion These results demonstrated adalimumab effectiveness in improving quality of life while reducing economic burden of active NIIPPU.

Objective: The objective of the study was to understand the reasons for the limited number of pharmaceutical-initiated clinical studies in the Middle East region, by assessing the knowledge, attitudes, and perceptions related to pharmaceutical-initiated clinical trials among health-care professionals (HCPs) in UAE, Qatar, Oman, Bahrain, and Jordan. Methods: The study was conducted using an online questionnaire-based survey. The HCP respondents were from UAE, Qatar, Oman, Bahrain, and Jordan and had a good understanding of the English language. Descriptive statistical analysis was used to analyze the responses. Results: The HCPs were not inclined toward participation in clinical trials and research activities. The reasons for their limited participation included a lack of time, resources, and limited awareness about their legal protection associated with such studies, and the lack of necessary training and education related to clinical research. Conclusions: Although there is a willingness to participate in clinical trials conducted by pharmaceutical companies, HCPs face various ethical, administrative, and academic barriers. Addressing these issues would help increase the number of trials conducted in the Middle East region.